다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
European journal of medicinal chemistry, v.229, 2022년, pp.114046 -
Stille, Julia K. (Department of Chemistry, McGill University) , Tjutrins, Jevgenijs (Department of Chemistry, McGill University) , Wang, Guanyu (Department of Chemistry, McGill University) , Venegas, Felipe A. (Department of Chemistry, McGill University) , Hennecker, Christopher (Department of Chemistry, McGill University) , Rueda, Andrés M. (Department of Chemistry, McGill University) , Sharon, Itai (Department of Biochemistry, McGill University) , Blaine, Nicole (Department of Chemistry, McGill University) , Miron, Caitlin E. (Department of Chemistry, McGill University) , Pinus, Sharon (Department of Chemistry, McGill University) , Labarre, Anne (Department of Chemistry, McGill University) , Plescia, Jessica (Department of Chemistry, McGill University) , Burai Patrascu, Mihai (Department of Chemistry, McGill University) , Zhang, Xiaocong (Department of Chemistry, McGill University) , Wahba, Alexander S. (Dep) , Vlaho, Danielle , Huot, Mitchell J. , Schmeing, T. Martin , Mittermaier, Anthony K. , Moitessier, Nicolas
AI-Helper
Abstract Severe diseases such as the ongoing COVID-19 pandemic, as well as the previous SARS and MERS outbreaks, are the result of coronavirus infections and have demonstrated the urgent need for antiviral drugs to combat these deadly viruses. Due to its essential role in viral replication and func...
1 https://www.who.int/
2 https://www.ecdc.europa.eu/en/publications-data/distribution-confirmed-cases-mers-cov-place-infection-and-month-onset-march-2012
3 Schlottau K. Rissmann M. Graaf A. Schön J. Sehl J. Wylezich C. Höper D. Mettenleiter T.C. Balkema-Buschmann A. Harder T. Grund C. Hoffmann D. Breithaupt A. Beer M. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study Lancet Micr 1 2020 E218 E225
4 Shi Z. Hu Z. A review of studies on animal reservoirs of the SARS coronavirus Virus Res. 133 2008 74 87 17451830
5 Abdollahi E. Champredon D. Langley J.M. Galvani A.P. Moghadas S.M. Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States Can. Med. Assoc. J. 192 2020 E666 E670 32444481
6 https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/
7 Organization W.H. WHO Coronavirus Disease 2020 COVID-19) Dashboard
8 Modi C. Böhm V. Ferraro S. Stein G. Seljak U. Estimating COVID-19 mortality in Italy early in the COVID-19 pandemic Nat. Commun. 12 2021 2729 33980836
9 Stankiewicz K. Pfizer's CEO Says Covid Vaccine Effectiveness Drops to 84% after Six Months 2021
10 Ledford H. Six months of COVID vaccines: what 1.7 billion doses have taught scientists Nature 594 2021 164 167 34089016
11 Dai L. Gao G.F. Viral targets for vaccines against COVID-19 Nat. Rev. Immunol. 21 2021 73 82 33340022
12 Chodick G. Tene L. Rotem R.S. Patalon T. Gazit S. Ben-Tov A. Weil C. Goldshtein I. Twig G. Cohen D. Muhsen K. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data Clin. Infect. Dis. 2021
13 Merck Merck Molnupiravir Ridgeback’s An Oral COVID-19 Antiviral Medicine 2021 Receives First Authorization in the World
14 Cannalire R. Cerchia C. Beccari A.R. Di Leva F.S. Summa V. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities J. Med. Chem. 2020
15 Zhou P. Yang X.-L. Wang X.-G. Hu B. Zhang L. Zhang W. Si H.-R. Zhu Y. Li B. Huang C.-L. Chen H.-D. Chen J. Luo Y. Guo H. Jiang R.-D. Liu M.-Q. Chen Y. Shen X.-R. Wang X. Zheng X.-S. Zhao K. Chen Q.-J. Deng F. Liu L.-L. Yan B. Zhan F.-X. Wang Y.-Y. Xiao G.-F. Shi Z.-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature 579 2020 270 273 32015507
16 Wu A. Peng Y. Huang B. Ding X. Wang X. Niu P. Meng J. Zhu Z. Zhang Z. Wang J. Sheng J. Quan L. Xia Z. Tan W. Cheng G. Jiang T. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China 2020 Cell Host & Microbe
17 Rathnayake A.D. Kim Y. Dampalla C.S. Nguyen H.N. Jesri A.-R.M. Kashipathy M.M. Lushington G.H. Battaile K.P. Lovell S. Chang K.-O. Groutas W.C. Structure-guided optimization of dipeptidyl inhibitors of norovirus 3CL protease J. Med. Chem. 2020
18 Kuo C.-J. Shie J.-J. Fang J.-M. Yen G.-R. Hsu J.T.A. Liu H.-G. Tseng S.-N. Chang S.-C. Lee C.-Y. Shih S.-R. Liang P.-H. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents Bioorg. Med. Chem. 16 2008 7388 7398 18583140
19 Dragovich P.S. Prins T.J. Zhou R. Webber S.E. Marakovits J.T. Fuhrman S.A. Patick A.K. Matthews D.A. Lee C.A. Ford C.E. Burke B.J. Rejto P.A. Hendrickson T.F. Tuntland T. Brown E.L. Meador J.W. Ferre R.A. Harr J.E.V. Kosa M.B. Worland S.T. Structure-based design, synthesis, and biological evaluation of irreversible human Rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as l-glutamine replacements J. Med. Chem. 42 1999 1213 1224 10197965
20 Jin Z. Du X. Xu Y. Deng Y. Liu M. Zhao Y. Zhang B. Li X. Zhang L. Peng C. Duan Y. Yu J. Wang L. Yang K. Liu F. Jiang R. Yang X. You T. Liu X. Yang X. Bai F. Liu H. Liu X. Guddat L.W. Xu W. Xiao G. Qin C. Shi Z. Jiang H. Rao Z. Yang H. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors Nature 582 2020 289 293 32272481
21 Su H.-x. Yao S. Zhao W.-f. Li M.-j. Liu J. Shang W.-j. Xie H. Ke C.-q. Hu H.-c. Gao M.-n. Yu K.-q. Liu H. Shen J.-s. Tang W. Zhang L.-k. Xiao G.-f. Ni L. Wang D.-w. Zuo J.-p. Jiang H.-l. Bai F. Wu Y. Ye Y. Xu Y.-c. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients Acta Pharmacol. Sin. 41 2020 1167 1177 32737471
22 Kneller D.W. Galanie S. Phillips G. O'Neill H.M. Coates L. Kovalevsky A. Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals Structure 28 2020 1313 1320 e1313 33152262
23 Kneller D.W. Phillips G. O'Neill H.M. Jedrzejczak R. Stols L. Langan P. Joachimiak A. Coates L. Kovalevsky A. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography Nat. Commun. 11 2020 3202 32581217
24 Pillaiyar T. Manickam M. Namasivayam V. Hayashi Y. Jung S.-H. An overview of severe acute respiratory syndrome–coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy J. Med. Chem. 59 2016 6595 6628 26878082
25 Zhang L. Lin D. Sun X. Curth U. Drosten C. Sauerhering L. Becker S. Rox K. Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Science 368 2020 409 412 32198291
26 Vuong W. Khan M.B. Fischer C. Arutyunova E. Lamer T. Shields J. Saffran H.A. McKay R.T. van Belkum M.J. Joyce M.A. Young H.S. Tyrrell D.L. Vederas J.C. Lemieux M.J. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication Nat. Commun. 11 2020 4282 32855413
28 Anand K. Ziebuhr J. Wadhwani P. Mesters J.R. Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs Science 300 2003 1763 1767 12746549
29 Liu C. Zhou Q. Li Y. Garner L.V. Watkins S.P. Carter L.J. Smoot J. Gregg A.C. Daniels A.D. Jervey S. Albaiu D. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases ACS Cent. Sci. 6 2020 315 331 32226821
30 Westberg M. Su Y. Zou X. Ning L. Hurst B. Tarbet B. Lin M.Z. Rational Design of a New Class of Protease Inhibitors for the Potential Treatment of Coronavirus Diseases 2020 bioRxiv 2020.2009.2015.275891
31 Iketani S. Forouhar F. Liu H. Hong S.J. Lin F.-Y. Nair M.S. Zask A. Huang Y. Xing L. Stockwell B.R. Chavez A. Ho D.D. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors Nat. Commun. 12 2021 2016
32 Boras B. Jones R.M. Anson B.J. Arenson D. Aschenbrenner L. Bakowski M.A. Beutler N. Binder J. Chen E. Eng H. Hammond J. Hoffman R. Kadar E.P. Kania R. Kimoto E. Kirkpatrick M.G. Lanyon L. Lendy E.K. Lillis J.R. Luthra S.A. Ma C. Noell S. Obach R.S. O’ Brien M.N. O'Connor R. Ogilvie K. Owen D. Pettersson M. Reese M.R. Rogers T.F. Rossulek M.I. Sathish J.G. Steppan C. Ticehurst M. Updyke L.W. Zhu Y. Wang J. Chatterjee A.K. Mesecar A.D. Anderson A.S. Allerton C. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19 2021 bioRxiv 2020.2009.2012.293498
33 Hoffman R. Kania R.S. Brothers M.A. Davies J.F. Ferre R.A. Gajiwala K.S. He M. Hogan R.J. Kozminski K. Li L.Y. Lockner J.W. Lou J. Marra M.T. Mitchell L.J.J. Murraya B.W. Nieman J.A. Noell S. Planken S.P. Rowe T. Ryan K. Smith G.J.I. Solowiej J.E. Steppan C.M. Taggart B. The discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19 ChemRxiv 2020 10.26434/chemrxiv.12631496.v1
34 Hoffman R.L. Kania R.S. Brothers M.A. Davies J.F. Ferre R.A. Gajiwala K.S. He M. Hogan R.J. Kozminski K. Li L.Y. Lockner J.W. Lou J. Marra M.T. Mitchell L.J. Murray B.W. Nieman J.A. Noell S. Planken S.P. Rowe T. Ryan K. Smith G.J. Solowiej J.E. Steppan C.M. Taggart B. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19 J. Med. Chem. 63 2020 12725 12747 33054210
35 Study of PF-07321332 in Healthy Participants - NCT04756531 2021
36 D.R. Owen, C.M.N. Allerton, A.S. Anderson, L. Aschenbrenner, M. Avery, S. Berritt, B. Boras, R.D. Cardin, A. Carlo, K.J. Coffman, A. Dantonio, L. Di, H. Eng, R. Ferre, K.S. Gajiwala, S.A. Gibson, S.E. Greasley, B.L. Hurst, E.P. Kadar, A.S. Kalgutkar, J.C. Lee, J. Lee, W. Liu, S.W. Mason, S. Noell, J.J. Novak, R.S. Obach, K. Ogilvie, N.C. Patel, M. Pettersson, D.K. Rai, M.R. Reese, M.F. Sammons, J.G. Sathish, R.S.P. Singh, C.M. Steppan, A.E. Stewart, J.B. Tuttle, L. Updyke, P.R. Verhoest, L. Wei, Q. Yang, Y. Zhu, An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19, Science, 0 eabl4784.
37 Pfizer Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization O Death by 89% in Iterim Analysis of Phase 2/3 EPIC-HR Study 2021
38 Bai B. Belovodskiy A. Hena M. Kandadai A.S. Joyce M.A. Saffran H.A. Shields J.A. Khan M.B. Arutyunova E. Lu J. Bajwa S.K. Hockman D. Fischer C. Lamer T. Vuong W. van Belkum M.J. Gu Z. Lin F. Du Y. Xu J. Rahim M. Young H.S. Vederas J.C. Tyrrell D.L. Lemieux M.J. Nieman J.A. Peptidomimetic α-acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability J. Med. Chem. 2021
39 Bai B. Arutyunova E. Khan M.B. Lu J. Joyce M.A. Saffran H.A. Shields J.A. Kandadai A.S. Belovodskiy A. Hena M. Vuong W. Lamer T. Young H.S. Vederas J.C. Tyrrell D.L. Lemieux M.J. Nieman J.A. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors RSC Med. Chem. 12 2021 1722 1730 34778773
40 Zhang L. Lin D. Kusov Y. Nian Y. Ma Q. Wang J. von Brunn A. Leyssen P. Lanko K. Neyts J. de Wilde A. Snijder E.J. Liu H. Hilgenfeld R. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment J. Med. Chem. 63 2020 4562 4578 32045235
41 Kim Y. Liu H. Galasiti Kankanamalage A.C. Weerasekara S. Hua D.H. Groutas W.C. Chang K.-O. Pedersen N.C. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor PLoS Pathog. 12 2016 e1005531
42 Vuong W. Fischer C. Khan M.B. van Belkum M.J. Lamer T. Willoughby K.D. Lu J. Arutyunova E. Joyce M.A. Saffran H.A. Shields J.A. Young H.S. Nieman J.A. Tyrrell D.L. Lemieux M.J. Vederas J.C. Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies Eur. J. Med. Chem. 222 2021 113584 34118724
43 Chen L.-R. Wang Y.-C. Lin Y.W. Chou S.-Y. Chen S.-F. Liu L.T. Wu Y.-T. Kuo C.-J. Chen T.S.-S. Juang S.-H. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors Bioorg. Med. Chem. Lett 15 2005 3058 3062 15896959
44 Zhang J. Huitema C. Niu C. Yin J. James M.N.G. Eltis L.D. Vederas J.C. Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase Bioorg. Chem. 36 2008 229 240 18295820
45 Zhang C.-H. Stone E.A. Deshmukh M. Ippolito J.A. Ghahremanpour M.M. Tirado-Rives J. Spasov K.A. Zhang S. Takeo Y. Kudalkar S.N. Liang Z. Isaacs F. Lindenbach B. Miller S.J. Anderson K.S. Jorgensen W.L. Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug Perampanel guided by free energy perturbation calculations ACS Cent. Sci. 2021
46 Drayman N. Jones K.A. Azizi S.-A. Froggatt H.M. Tan K. Maltseva N.I. Chen S. Nicolaescu V. Dvorkin S. Furlong K. Kathayat R.S. Firpo M.R. Mastrodomenico V. Bruce E.A. Schmidt M.M. Jedrzejczak R. Muñoz-Alía M.Á. Schuster B. Nair V. Botten J.W. Brooke C.B. Baker S.C. Mounce B.C. Heaton N.S. Dickinson B.C. Jaochimiak A. Randall G. Tay S. Drug Repurposing Screen Identifies Masitinib as a 3CLpro Inhibitor that Blocks Replication of SARS-CoV-2 in Vitro 2020 bioRxiv 2020.2008.2031.274639
47 Zhu W. Xu M. Chen C.Z. Guo H. Shen M. Hu X. Shinn P. Klumpp-Thomas C. Michael S.G. Zheng W. Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening ACS Pharmacol. Transl. Sci. 2020
48 De Cesco S. Kurian J. Dufresne C. Mittermaier A. Moitessier N. Covalent inhibitors design and discovery Eur. J. Med. Chem. 138 2017 96 114 28651155
49 Zhou S. Chan E. Duan W. Huang M. Chen Y.Z. Drug Bioactivation, Covalent Binding to Target Proteins and Toxicity Relevance 2005 Drug Metab. Rev. 41 213
50 Guterman L. Covalent drugs form long-lived ties C&EN 89 2011 19 26
51 Tang B. He F. Liu D. Fang M. Wu Z. Xu D. AI-aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2 bioRxiv 2020 2020.2003.2003.972133
52 Nguyen D.D. Gao K. Chen J. Wang R. Wei G.-W. Potentially Highly Potent Drugs for 2019-nCoV 2020 bioRxiv 2020.2002.2005.936013
53 Roy R. Sk M.F. Jonniya N.A. Poddar S. Kar P. Finding Potent Inhibitors against SARS-CoV-2 Main Protease through Virtual Screening, ADMET, and Molecular Dynamic Simulation Studies 2020 ChemRxiv Preprint
54 Mariaule G. De Cesco S. Airaghi F. Kurian J. Schiavini P. Rocheleau S. Huskić I. Auclair K. Mittermaier A. Moitessier N. 3-Oxo-hexahydro-1H-isoindole-4-carboxylic acid as a drug chiral bicyclic scaffold: structure-based design and preparation of conformationally constrained covalent and noncovalent prolyl oligopeptidase inhibitors J. Med. Chem. 59 2016 4221 4234 26619267
55 Plescia J. Dufresne C. Janmamode N. Wahba A.S. Mittermaier A.K. Moitessier N. Discovery of covalent prolyl oligopeptidase boronic ester inhibitors Eur. J. Med. Chem. 185 2020 111783 31732257
56 Jacobs J. Grum-Tokars V. Zhou Y. Turlington M. Saldanha S.A. Chase P. Eggler A. Dawson E.S. Baez-Santos Y.M. Tomar S. Mielech A.M. Baker S.C. Lindsley C.W. Hodder P. Mesecar A. Stauffer S.R. Discovery, synthesis, and structure-based optimization of a series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease J. Med. Chem. 56 2013 534 546 23231439
57 Zaidman D. Gehrtz P. Filep M. Fearon D. Prilusky J. Duberstein S. Cohen G. Owen D. Resnick E. Strain-Damerell C. Lukacik P. Barr H. Walsh M.A. von Delft F. London N. An Automatic Pipeline for the Design of Irreversible Derivatives Identifies a Potent SARS-CoV-2 Mpro Inhibitor 2020 bioRxiv 2020.2009.2021.299776
58 Mesecar A.D. Structure of COVID-19 Main Protease Bound to Potent Broad-Spectrum Non-covalent Inhibitor X77 2020 10.2210/pdb2216W2263/pdb
59 Moitessier N. Pottel J. Therrien E. Englebienne P. Liu Z. Tomberg A. Corbeil C.R. Medicinal chemistry projects requiring imaginative structure-based drug design methods Acc. Chem. Res. 49 2016 1646 1657 27529781
60 Behnke D. Taube R. Illgen K. Nerdinger S. Herdtweck E. Substituted 2-(Cyanomethyl-amino)-acetamides by a novel three-component reaction Synlett 2004 688 692 2004
61 Gedey S. Van der Eycken J. Fülöp F. Liquid-phase combinatorial synthesis of alicyclic β-lactams via Ugi four-component reaction Org. Lett. 4 2002 1967 1969 12027659
62 Dhake K.P. Tambade P.J. Singhal R.S. Bhanage B.M. An efficient, catalyst- and solvent-freeN-formylation of aromatic and aliphatic amines Green Chem. Lett. Rev. 4 2011 151 157
63 Patil P. Ahmadian-Moghaddam M. Dömling A. Isocyanide 2.0 Green Chem. 22 2020 6902 6911
64 St John S.E. Mesecar A.D. Broad Spectrum Non-covalent Coronavirus Protease Inhibitors USA 2018
65 Petri L. Egyed A. Bajusz D. Imre T. Hetényi A. Martinek T. Ábrányi-Balogh P. Keserű G.M. An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases Eur. J. Med. Chem. 207 2020 112836 32971426
66 Turlington M. Chun A. Tomar S. Eggler A. Grum-Tokars V. Jacobs J. Daniels J.S. Dawson E. Saldanha A. Chase P. Baez-Santos Y.M. Lindsley C.W. Hodder P. Mesecar A.D. Stauffer S.R. Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding Bioorg. Med. Chem. Lett 23 2013 6172 6177 24080461
67 Di Trani J.M. De Cesco S. O'Leary R. Plescia J. do Nascimento C.J. Moitessier N. Mittermaier A.K. Rapid measurement of inhibitor binding kinetics by isothermal titration calorimetry Nat. Commun. 9 2018 893 29497037
68 Bevington P.R. Robinson D.K. Data Reduction and ErrorAnalysis for the Physical Sciences 1992 WCB/McGraw-Hill New York
69 Kitamura N. Sacco M.D. Ma C. Hu Y. Townsend J.A. Meng X. Zhang F. Zhang X. Ba M. Szeto T. Kukuljac A. Marty M.T. Schultz D. Cherry S. Xiang Y. Chen Y. Wang J. Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors J. Med. Chem. 2021
70 Steuten K. Kim H. Widen J.C. Babin B.M. Onguka O. Lovell S. Bolgi O. Cerikan B. Neufeldt C.J. Cortese M. Muir R.K. Bennett J.M. Geiss-Friedlander R. Peters C. Bartenschlager R. Bogyo M. Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 ACS Infect. Dis. 2021
71 Zhao M.-M. Yang W.-L. Yang F.-Y. Zhang L. Huang W.-J. Hou W. Fan C.-F. Jin R.-H. Feng Y.-M. Wang Y.-C. Yang J.-K. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development Signal Transduct. Target. Ther. 6 2021 134 33774649
72 Rogachev V.O. Metz P. Thermal and high pressure intramolecular Diels–Alder reaction of vinylsulfonamides Nat. Protoc. 1 2006 3076 3087 17406571
73 Xue X. Yang H. Shen W. Zhao Q. Li J. Yang K. Chen C. Jin Y. Bartlam M. Rao Z. Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction J. Mol. Biol. 366 2007 965 975 17189639
74 Hanahan D. Studies on transformation of Escherichia coli with plasmids J. Mol. Biol. 166 1983 557 580 6345791
75 Chen S. Chen L.-l. Luo H.-b. Sun T. Chen J. Ye F. Cai J.-h. Shen J.-k. Shen X. Jiang H.-l. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique Acta Pharmacol. Sin. 26 2005 99 106 15659121
76 McCoy A.J. Grosse-Kunstleve R.W. Adams P.D. Winn M.D. Storoni L.C. Read R.J. Phaser crystallographic software J. Appl. Crystallogr. 40 2007 658 674 19461840
77 Long F. Nicholls R.A. Emsley P. Graǽulis S. Merkys A. Vaitkus A. Murshudov G.N. Validation and extraction of molecular-geometry information from small-molecule databases Acta Crystallogr. D Struct. Biol. 73 2017 103 111 28177306
78 Potterton L. Agirre J. Ballard C. Cowtan K. Dodson E. Evans P.R. Jenkins H.T. Keegan R. Krissinel E. Stevenson K. Lebedev A. McNicholas S.J. Nicholls R.A. Noble M. Pannu N.S. Roth C. Sheldrick G. Skubak P. Turkenburg J. Uski V. von Delft F. Waterman D. Wilson K. Winn M. Wojdyr M. CCP4i2: the new graphical user interface to the CCP4 program suite Acta Crystallogr. D Struct. Biol. 74 2018 68 84 29533233
79 Skubák P. Murshudov G.N. Pannu N.S. Direct incorporation of experimental phase information in model refinement Acta Crystallogr. D Biol. Crystallogr. 60 2004 2196 2201 15572772
80 Emsley P. Cowtan K. Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132 15572765
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.